Linked Life Data

2911851

Source:http://linkedlifedata.com/resource/pubmed/id/2911851

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
1
pubmed:dateCreated
1989-2-14
pubmed:abstractText
The current study was performed to document the cost savings and need for a therapeutic drug monitoring program for phenytoin. The methodology employed a prospective, randomized, crossover design that utilized two control and two therapeutic drug monitoring phases. The therapeutic drug monitoring program significantly decreased the average number of assays performed per patient from 2.14 to 0.61. Withdrawal of the program resulted in a significant increase in the average number of assays performed per patient (from 0.61 to 2.41), the average number of assays drawn incorrectly (from 0.39 to 1.89), and in the average number of assays used inappropriately (from 0.50 to 2.07). Withdrawal of the program was also associated with a significant increase in the average number of readmissions (from 0 to 0.19) within 3 months of discharge. Reinstitution of the program was associated with a significant decrease in the average number of readmissions (from 0.19 to 0.03) within 3 months of discharge. The cost savings from decreasing the number of assays performed was estimated to be $100.00 for the first year.
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:issn
0163-4356
pubmed:author
pubmed:issnType
Print
pubmed:volume
11
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
32-7
pubmed:dateRevised
2007-11-15
pubmed:meshHeading
pubmed:year
1989
pubmed:articleTitle
The impact of a therapeutic drug monitoring program for phenytoin.
pubmed:affiliation
Pharmacy Department, Foothills Hospital, Calgary, Alberta, Canada.
pubmed:publicationType
Journal Article, Clinical Trial, Randomized Controlled Trial, Research Support, Non-U.S. Gov't